![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Summary
Sodium cromoglycate formulated as a pressurized aerosol (2 mg 4-times daily) and placebo were compared in 31 adult asthmatic patients in a double-blind crossover trial lasting 12 weeks. Sodium cromoglycate was superior to placebo in improving breathlessness at rest (p<0.001), breathlessness on exertion (p<0.05) and the quality of sleep (p<0.001), and also in improving the morning peak expiratory flow rate value (p<0.05). Both the patients’ (p<0.05) and the clinicians’ (p<0.01) treatment opinions, and their treatment preferences (p<0.05), favoured sodium cromoglycate. Moreover, usage of bronchodilators (theophylline and aerosol beta-stimulants combined) declined significantly (p<0.001) during sodium cromoglycate treatment compared to placebo. No side-effects were reported. The results of this study show that sodium cromoglycate delivered by pressurized aerosol was significantly superior to placebo, not only in improving asthmatic symptoms, but also in reducing the amount of concomitant bronchodilator therapy required.
Key Words::